Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Integrated BioTherapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Integrated BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Integrated BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Integrated BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Integrated BioTherapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Integrated BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Integrated BioTherapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Integrated BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Integrated BioTherapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Integrated BioTherapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Integrated BioTherapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Integrated BioTherapeutics, Inc. Snapshot 5 Integrated BioTherapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Integrated BioTherapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Integrated BioTherapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Integrated BioTherapeutics, Inc. - Pipeline Products Glance 11 Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Integrated BioTherapeutics, Inc. - Drug Profiles 14 STEBVax 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 AT-62-aa 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibody 3 for Staphylococcus Aureus Infections 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 panfilovirus (multivalent) vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SEB-HuMab 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 staphylococcal [serogroup A] (multivalent) vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 staphylococcus aureus (bivalent) vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 staphylococcus aureus (multivalent) vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibodies for Ebola and Marburg Infections 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody 1 for Staphylococcus Aureus Infections 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody 2 for Staphylococcus Aureus Infections 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibody 4 for Staphylococcus Aureus Infections 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Integrated BioTherapeutics, Inc. - Pipeline Analysis 30 Integrated BioTherapeutics, Inc. - Pipeline Products by Target 30 Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration 31 Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type 32 Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 33 Integrated BioTherapeutics, Inc. - Recent Pipeline Updates 34 Integrated BioTherapeutics, Inc. - Dormant Projects 35 Integrated BioTherapeutics, Inc. - Locations And Subsidiaries 36 Head Office 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Integrated BioTherapeutics, Inc., Key Information 5 Integrated BioTherapeutics, Inc., Key Facts 5 Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2014 8 Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Integrated BioTherapeutics, Inc. - Phase I, 2014 11 Integrated BioTherapeutics, Inc. - Preclinical, 2014 12 Integrated BioTherapeutics, Inc. - Discovery, 2014 13 Integrated BioTherapeutics, Inc. - Pipeline by Target, 2014 30 Integrated BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014 31 Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014 32 Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 33 Integrated BioTherapeutics, Inc. - Recent Pipeline Updates, 2014 34 Integrated BioTherapeutics, Inc. - Dormant Developmental Projects,2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.